Immunosuppressive Drugs

Chair

Florian Lemaitre
Rennes, France

Vice-Chair

Nuria Lloberas
Barcelona, Spain

Committee Purpose

  • To provide evidence-based recommendations for TDM of immunosuppressive agents.
  • To promote the knowledge and understanding of immunosuppressive drug analysis and interpretation of results.
  • To enhance communication between scientists and physicians of all disciplines involved in TDM of immunosuppressive drugs.
  • To encourage the effective application of TDM in transplant medicine, with the aim of optimizing clinical drug use and maximizing the clinical and economic benefits.
  • Consensus document on Cyclosporine therapeutic drug monitoring and treatment personalization (Leader: U. Christians)
  • Ideal practice guidelines document on immunosuppressive drug treatment personalization with the European Society of Organ Transplantation (Leader: F. Lemaitre)
  • Special issue on transplantation pharmacology in Therapeutic Drug Monitoring

2023: Everolimus Personalized Therapy: Second Version of Consensus Document by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJ, Noceti O, Oellerich M, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Vethe NT, Walson P, Woillard JB, Langman LJ. Submitted.

2023: Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, Venkataramanan R, Elens L, Moes DJAR, Hesselink DA, Pawinski T, Johnson-Davis KL, De Winter BCM, Pattanaik S, Brunet M, Masuda S, Langman LJ.., Ther Drug Monit. 2023 Apr 1;45(2):191-199

2023: TDM is Alive and Kicking! Lemaitre F, Hesselink DA. Ther Drug Monit. 2023 Feb 1;45(1):3-5.